Home » Stocks » Freeline Therapeutics

Freeline Therapeutics Holdings PLC (FRLN)

Stock Price: $16.91 USD -0.28 (-1.63%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 587.53M
Revenue (ttm) n/a
Net Income (ttm) -53.91M
Shares Out 34.74M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $16.91
Previous Close $17.19
Change ($) -0.28
Change (%) -1.63%
Day's Open 17.45
Day's Range 16.30 - 18.00
Day's Volume 145,272
52-Week Range 15.25 - 21.69

More Stats

Market Cap 587.53M
Enterprise Value 513.83M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 34.74M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -8.71
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.15M
Short Ratio 1.63
Short % of Float 0.00%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 7.03
Revenue n/a
Operating Income -63.64M
Net Income -53.91M
Free Cash Flow -55.30M
Net Cash 73.70M
Net Cash / Share 2.12
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -51.20%
ROE -99.90%
ROIC -595.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$28.75*
(70.02% upside)
Low
27.0
Current: $16.91
High
32.0
Target: 28.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue--
Operating Income-63.64-40.98
Net Income-53.91-33.28
Shares Outstanding6.354.62
Earnings Per Share-8.49-7.20
Operating Cash Flow-52.32-25.77
Capital Expenditures-2.98-3.71
Free Cash Flow-55.30-29.49
Cash & Equivalents73.7016.05
Net Cash / Debt73.7016.05
Assets97.3932.13
Liabilities12.439.16
Book Value84.9622.97
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Freeline Therapeutics Holdings PLC
Country United Kingdom
Employees 200
CEO Theresa Heggie

Stock Information

Ticker Symbol FRLN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FRLN
IPO Date August 7, 2020

Description

Freeline Therapeutics Holdings plc operates as a clinical-stage systemic adeno-associated virus (AAV)-based gene therapy company. Its advanced product candidate is FLT180a, a gene therapy product candidate that is being evaluated in a Phase 1/2 dose-finding clinical trials in adult males for the treatment of patients with moderate or severe hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. Address: Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX